Bio-Rad Laboratories, Inc. BIO
371.85 USD -3.06 (-0.82%)
Nov 4, 2026, 10:56 AM EST
371.85 Day range 380.87
236.73 52-week range 396.23
- YTD
- +22.73%
- 1 year
- +19.58%
Analyst view
Consensus: hold
Hold
Price target (mean) 335.00 -9.9% downside
Now 371.85
- Target (low)
- 280.00
- Target (mean)
- 335.00
- Target (high)
- 390.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
- Strong buy1
- Buy0
- Hold1
- Sell0
- Strong sell1
Recommendation trend
- This month 3
- 1 month ago 3
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.23 | 2.16 – 2.29 | 2.26 | -1.6% | 649.95M | -0.5% | 2 |
| Next quarter | 3.02 | 2.74 – 3.30 | 2.51 | +20.3% | 695.40M | +0.3% | 2 |
| Current year | 9.45 | 8.85 – 10.10 | 9.92 | -4.7% | 2.57B | -0.5% | 3 |
| Next year | 9.75 | 8.75 – 10.90 | 9.45 | +3.1% | 2.62B | +2.1% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 5, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Aug 5, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 5, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| May 1, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Apr 7, 2026 | Citigroup | Downgrade | Buy | Neutral |
| Feb 16, 2026 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Oct 30, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 30, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Aug 1, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 1, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jun 9, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| May 2, 2025 | UBS | Maintained | Buy | Buy |
| May 2, 2025 | Citigroup | Maintained | Buy | Buy |
| May 2, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 17, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Feb 12, 2025 | Wells Fargo | Maintained | Equal-Weight | Equal-Weight |
| Jan 14, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| Dec 9, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 31, 2024 | Citigroup | Maintained | Buy | Buy |
| Oct 31, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 1, 2024 | Citigroup | Upgrade | Neutral | Buy |
| Aug 27, 2024 | Wells Fargo | Initiated | — | Equal-Weight |
| Aug 16, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 2, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 2, 2024 | Citigroup | Maintained | Neutral | Neutral |
| May 8, 2024 | UBS | Maintained | Buy | Buy |
| Apr 3, 2024 | Citigroup | Downgrade | Buy | Neutral |
| Feb 16, 2024 | UBS | Maintained | Buy | Buy |
| Feb 16, 2024 | RBC Capital | Maintained | Outperform | Outperform |
